5-MeO-DMT Recrystallization for Pharmaceutical-Grade Purity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for purifying 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) do not achieve the high purity required for pharmaceutical use, with total impurities exceeding 0.5% and individual impurities above 0.1%, and residual solvent levels not meeting specifications.
Innovation Solution
A recrystallization method using solvents comprising ethers with specific boiling points and limited aliphatic hydrocarbons as anti-solvents, involving dissolution above room temperature, cooling to precipitate solid 5-MeO-DMT, and solvent removal under reduced pressure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If distillation under reduced pressure is used to purify 5-MeO-DMT, then some purification is achieved, but the high boiling point makes it inefficient and impurities remain above 0.5%
Solution Approach 1:
The patent changes the purification parameter from distillation temperature/pressure to solvent-based recrystallization temperature. By dissolving crude 5-MeO-DMT in a suitable solvent at elevated temperature and then cooling to precipitate pure crystals, the method achieves pharmaceutical-grade purity (>99.5%) without the inefficiencies of distillation given the compound's high boiling point.
Solution Approach 2:
The patent utilizes the phase transition of 5-MeO-DMT from dissolved state to crystalline solid state through controlled cooling. This recrystallization process selectively precipitates pure 5-MeO-DMT crystals while leaving impurities in the mother liquor, achieving high purity separation without requiring distillation.
2Manufacturing precision
If column chromatography is used to purify 5-MeO-DMT, then impurities can be reduced, but the process becomes complex and time-consuming
Solution Approach 1:
The patent extracts 5-MeO-DMT from the crude mixture by selective crystallization. By using a suitable solvent system and controlling temperature, pure 5-MeO-DMT crystals are extracted from the solution, leaving impurities behind in the mother liquor. This single extraction step replaces complex multi-step chromatography procedures.
Solution Approach 2:
The purification process relies on the self-organizing property of 5-MeO-DMT to crystallize in pure form from solution. The compound's inherent crystallization behavior is exploited to automatically separate it from impurities without requiring complex chromatography columns or multiple purification stages.
3Manufacturing precision
If traditional recrystallization with high anti-solvent content is used, then crystallization occurs, but impurity removal is insufficient and purity remains below pharmaceutical grade
Solution Approach 1:
The patent optimizes the solvent composition parameter, specifically limiting aliphatic hydrocarbons to less than 5 wt% instead of using traditional high anti-solvent content systems. This modified solvent composition, combined with controlled temperature cycling, achieves both high crystallization efficiency and pharmaceutical-grade purity by selectively incorporating 5-MeO-DMT into the crystal lattice while excluding impurities.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves 5-MeO-DMT with total impurities below 0.5% and individual impurities below 0.1%, along with low residual solvent content, suitable for pharmaceutical applications.
Implementation Method 1
dissolving crude 5-MeO-DMT in a solvent at a temperature above room temperature; cooling the obtained solution to a temperature below room temperature to precipitate solid 5-MeO-DMT
Implementation Method 2
dissolving crude 5-MeO-DMT in a solvent at a temperature above room temperature; cooling the obtained solution to a temperature below room temperature to precipitate solid 5-MeO-DMT
Implementation Method 3
wherein the solvent comprises one or more ethers and less than 5 wt % of aliphatic hydrocarbons as anti-solvents
Data Source
AI summary
A method of purifying 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is provided which comprises dissolving crude 5-MeO-DMT in a solvent at a temperature above room temperature, cooling the obtained solution to a temperature below room temperature to precipitate solid 5-MeO-DMT, separating the solid 5-MeO-DMT from the remaining solution and removing solvent from the crystalline 5-MeO-DMT. In the method, the solvent comprises one or more ethers and less than 5 wt % anti-solvent.